Clinical trials help doctors find better ways to treat and prevent cancer. If you or a loved one has cancer, you might consider joining a clinical trial in order to try a new drug or treatment, or help doctors develop better treatments for the future. Learn more about clinical trials

Browse our list of lymphoma clinical trials below, or search our clinical trials database by cancer type, drug, doctor, or protocol.

Disease Study # Study Title and Description PI
Relapsed/Refractory E4412-CIRB A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma Anne Beaven, MD
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Marcie Riches, MD, MS
Relapsed LCCC1606-ATL Phase I Study of the Administration of T lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma Natalie Grover, MD
Relapsed (HIV) AMC-095 A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma Michael Lee, MD
Disease Study # Study Title and Description PI
Relapsed/Refractory LCCC1813-ATL A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects with Relapsed/Refractory B-cell Lymphoma Natalie Grover, MD
Relapsed/Refractory LOXO-BTK-18001 A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin’s Lymphoma (NHL) Catherine Coombs, MD
Disease Study # Study Title and Description PI
Frontline EA4151-CIRB A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission Anne Beaven, MD
Disease Study # Study Title and Description PI

Frontline

AMC-101 A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas (ARL) Christopher Dittus, DO, MPH

Any (HIV)

AMC-083 Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies Christopher Dittus, DO, MPH
Frontline (DEL or DHL) A051701 Randomized phase II/III study of venetoclax (ABT-199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double expressing lymphomas Christopher Dittus, DO, MPH
Disease Study # Study Title and Description PI

Frontline

LCCC1637

Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group Christopher Dittus, DO, MPH
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Marcie Riches, MD, MS
Relapsed LCCC1532-ATL Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma Anne Beaven, MD
Disease Study # Study Title and Description PI
Relapsed LCCC1606-ATL Phase I Study of the Administration of T lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma Natalie Grover, MD
Disease Study # Study Title and Description PI

Relapsed

EBV-CTL-201

Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable Option Marcie Riches, MD, MS
Disease Study # Study Title and Description PI
Relapsed AHOD1721-CA209744 Risk-Based, Response-Adapted, Phase II Open-Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults with Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-Line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants with a Suboptimal Response. Checkmate 744 Stuart Gold, MD
Relapsed LCCC1532-ATL Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma Anne Beaven, MD
Relapsed LCCC1524-ATL Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Marcie Riches, MD, MS
Frontline AHOD1331 A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents Stuart Gold, MD